T-knife
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Robert-rossle-str 10, Berlin, Berlin, 13...Phone Number
+49 3094892432Website
www.t-knife.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About T-knife
Founded in 2018 and headquartered in Berlin, Germany, T-knife is a spin-off from Max-Delbruck Center for Molecular Medicine with support from Charité University Hospital to provide novel, sophisticated T cell receptor-based therapeutics to market.Explore more
T-knife Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is T-knife your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when T-knife launches new products
Earning: See what the market has to say on T-knife recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if T-knife had a recent Job posting/layoffs
T-knife, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if T-knife is spiking on competitors!
Funding: Get notified immidiatlly once T-knife has new funding data
Congratulate Masked Content for being promoted to Masked Content at T-knife
Check if T-knife has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at T-knife
Find 3 more new buyers
Company Profile Activity
Activity Insights
T-knife is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
T-knife is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about T-knife.
T-knife financials insights
Gather financial insights about T-knife, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$77.2M
2021
Series B
$110M
T-knife Tech Stack
A closer look at the technologies used by T-knife
See more technologies
Most Recent Scoops
Project
Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Left Company
Executive Move
T-knife has announced that Megan Baierlein, Senior Vice President & Chief Operating Officer, has left the organization to join Third Rock Ventures (Newco) as Chief Operating Officer.
New Hire
Executive Move
Left Company
Executive Move
New Hire
Executive Move
T-knife News & Media
T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturingT-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 -- PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, lungs, breasts, esophagus, kidneys, cervix, and head & neckT-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress
-- Integrating a computational workflow that leverages multi-omics data with a proprietary, humanized in vivo screening platform, T-knife identified highly immunogenic solid-tumor antigens not previously recognized as functional
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding T-knife
Sign Up For FreeTo access detailed company insights
Founded in 2018 and headquartered in Berlin, Germany, T-knife is a spin-off from Max-Delbruck Center for Molecular Medicine with support from Charité University Hospital to provide novel, sophisticated T cell receptor-based therapeutics to market.... Read More
